Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 10/20 | 0.39 |
| ▸ | HCK | P08631 | 4/20 | 0.39 |
| ▸ | EGFR | P00533 | 5/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | CCNK | O75909 | 5/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 5/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509034 | 1.00 | LCK (0.43) | LCKMAPK14TP53MAPTBTK | |
| SCHEMBL509174 | 0.89 | LCK (0.46) | LCKMAPK14TP53MAPTBTK | |
| SCHEMBL509175 | 0.89 | LCK (0.46) | LCKMAPK14TP53MAPTBTK | |
| SCHEMBL13360635 | 0.86 | LCK (0.38) | LCKMAPK14BTKHCKEGFR | |
| SCHEMBL10187626 | 0.78 | LCK (0.37) | LCKMAPK14BTKHCKEGFR | |
| SCHEMBL508541 | 0.78 | ACHE (0.41) | TP53MAPTBTKEGFRCCNK | |
| SCHEMBL508540 | 0.78 | ACHE (0.41) | TP53MAPTBTKEGFRCCNK | |
| SCHEMBL10188141 | 0.74 | MEN1 (0.41) | MAPT | |
| SCHEMBL3353914 | 0.73 | FLT3 (0.38) | TP53MAPTEGFROGA | |
| SCHEMBL13360637 | 0.73 | NPSR1 (0.41) | MAPTCCNKCDK12EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028981-A1 | Kinase Knockdown Via Electrophilically Enhanced Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028981-A1 | Kinase Knockdown Via Electrophilically Enhanced Inhibitors | MAP3K20, MAP3K6, MAP3K19 | LCK 208/4885MAPK14 187/4885TP53 691/4885 |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | MAP3K20, MAP3K6, MAP3K19 | LCK 208/4885MAPK14 187/4885TP53 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.